Positive opinions were given for the first-line use of the immunotherapy combination nivolumab and ipilimumab in kidney cancer and for an extension of indication for blinatumomab in certain leukemia patients.
International Approvals
Original Article: EU Changes Mind on Nivo Plus Ipi for Kidney Cancer